Year: 2025
Type: article
Study design: Observational Study
Abstract: Introduction: Central venous access is essential for the administration of chemotherapy or immunotherapy in cancer treatment, with fully and semi-implantable devices associated with greater safety, comfort, and durability compared to other methods.Objective: To analyze hospital records regarding the implantation of fully and semi-implantable central venous catheters, assessing trends in hospitalization, costs, prevalence, and mortality. Methods: This was an observational, retrospective, and descriptive study using secondary data from the SUS Hospital Information System (SIH/SUS), extracted from DATASUS. The variables analyzed included the number of hospitalizations, average length of stay, total cost, prevalence rate and mortality rate. Results: Between 2008 and 2024, implantations increased by more than 600% (from 2,892 to 20,736 procedures), with the highest annual growth between 2022 and 2023. The average hospital stay reduced from 4.0 to 1.5 days. The total cost increased from US$273,583.43 to US$2,287,534.09. The prevalence increased from 1.5 to 8.7 per 1,000 hospitalizations, and mortality decreased from 2.56% to 0.89%, despite intermediate fluctuations.Conclusion: There was a significant increase in the implantation of central venous catheters for immunotherapy and chemotherapy in the SUS, with a reduction in hospital stay and mortality. Costs increased proportionally to the expansion of the procedure.
Authors: Wagner Ramos Borges, Aline Paiva Vaz Sampaio Ribeiro, Larissa de Araújo Marques Regis, Alice Sarno Menezes, Breno Leal Mota Silva
Language: English
Subfield: Emergency Medical Services
Field: Health Professions
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4414852601
FWCI:
Cites:
Cited by:
Related to: